French Polynesia vs Naoero: Prevalence rate of obesity in adults
French Polynesia
49.2%
in 2024
Naoero
71.4%
in 2024
French Polynesia rank
9th
Naoero rank
4th
Prevalence rate of obesity in adults over time
- French Polynesia
- Naoero
How they compare
Naoero currently reports 71.4% against 49.2% in French Polynesia, a difference of 22.2%.
That makes Naoero's figure about 1.5 times French Polynesia's.
Across all 45 years both countries report, Naoero has been ahead every year.
French Polynesia ranks 9th and Naoero ranks 4th of 199 countries.
Naoero has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | French Polynesia | Naoero | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 30.6% | 65.5% | 34.9% | Naoero |
| 1990s | 36.1% | 66.3% | 30.2% | Naoero |
| 2000s | 40.1% | 66.2% | 26.1% | Naoero |
| 2010s | 44.4% | 68.5% | 24.0% | Naoero |
| 2020s | 48.1% | 70.7% | 22.6% | Naoero |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, French Polynesia or Naoero?
- Naoero, at 71.4% against 49.2% in French Polynesia as of 2024.
- What is the difference in prevalence rate of obesity in adults between French Polynesia and Naoero?
- 22.2%, with Naoero ahead.
- How many years of comparable data are there for French Polynesia and Naoero?
- 45 years are reported by both, from 1980 to 2024.
- How do French Polynesia and Naoero rank globally for prevalence rate of obesity in adults?
- French Polynesia ranks 9th and Naoero ranks 4th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.